Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Metastatic hormone-sensitive prostate cancer, drawn from the whole corpus: 32 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Who needs triplet therapy and who is overtreated by it.
Whether intermittent or de-escalated therapy is safe after a deep PSA response.
PSMA PET restages many men the trials called non-metastatic, and the evidence has not caught up.
Background: Oligometastatic disease. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 33 changes by month →When this page itself was last checked or edited.
PSMA+ metastatic hormone-sensitive prostate cancer with ARPI (PSMAddition)
A milestone in how this cancer is treated.
mHSPC with ADT alone (ARANOTE)
Median rPFS 33.
Radiographic progression-free survival hazard ratio 1.